We investigated the pharmacokinetics of oral tacrolimus in 31 hematopoietic cell transplant recipients, identifying 2 subgroups based on the differences between C0 (trough) and Cmax (maximal) levels: group A (n = 21; 68%) with a Cmax-C0 value of <10 ng/mL, and group B (n = 10; 32%) with a Cmax-C0 value of ≥10 ng/mL. Although the C0 and C12 values were not significantly different between the 2 groups, the mean area under the concentration curve for 12 hours (AUC0-12) was significantly greater in group B than group A (200.9 ± 36.3 vs 155.1 ± 43.1 ng · h/mL; P < .05), and the mean half-life was significantly shorter in group B than group A (13.55 ± 6.70 vs 18.17 ± 6.30 hours; P < .05). Thus after the oral administration of tacrolimus, we observed a notably high AUC due to high peak level, which we were unable to predict simply by measuring the trough level. A pharmacokinetic analysis of each patient was essential to optimize the oral tacrolimus dose.
|出版ステータス||Published - 2009 6|
ASJC Scopus subject areas